Cargando…

Fever of Unknown Origin and Multidrug Resistant Organism Colonization in AML Patients

BACKGROUND: Colonization by multidrug-resistant organisms (MDRO) is a frequent complication in hematologic departments, which puts patients at risk of life-threatening bacterial sepsis. Fever of unknown origin (FUO) is a condition related to the delivery of chemotherapy in hematologic malignancies,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guarnera, Luca, Trotta, Gentiana Elena, Boldrini, Valentina, Cardillo, Lucia, Cerroni, Ilaria, Mezzanotte, Valeria, Pasqualone, Gianmario, Savi, Arianna, Borsellino, Beatrice, Buzzatti, Elisa, Palmieri, Raffaele, Paterno, Giovangiacinto, Maurillo, Luca, Buccisano, Francesco, Venditti, Adriano, Del Principe, Maria Ilaria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833311/ https://www.ncbi.nlm.nih.gov/pubmed/36660358 http://dx.doi.org/10.4084/MJHID.2023.013

Ejemplares similares

Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML
por: Meddi, Elisa, et al.
Publicado: (2023)

Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience
por: Paterno, Giovangiacinto, et al.
Publicado: (2022)

Case report: A Saprochaete clavata (Magnusiomyces clavatus) severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma
por: Pasqualone, Gianmario, et al.
Publicado: (2022)

Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness
por: Palmieri, Raffaele, et al.
Publicado: (2020)

Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia
por: Buzzatti, Elisa, et al.
Publicado: (2022)

Real-life experience of secondary prophylaxis with DOACs in splanchnic venous thrombosis during COVID-19 pandemic
por: Guarnera, Luca, et al.
Publicado: (2023)

Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

Therapy-related Myeloid Neoplasms: Considerations for Patients’ Clinical Evaluation
por: Palmieri, Raffaele, et al.
Publicado: (2023)

Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial
por: Buccisano, Francesco, et al.
Publicado: (2022)

PB1835: THE ISTH-DIC SCORE PREDICTS 30-DAYS OUTCOME IN NON-M3 ACUTE MYELOID LEUKEMIA PATIENTS
por: Paterno, G., et al.
Publicado: (2022)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
por: Buccisano, Francesco, et al.
Publicado: (2022)

Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia
por: Aureli, Anna, et al.
Publicado: (2021)

Treatment of Low-Blast Count AML using Hypomethylating Agents
por: De Bellis, Eleonora, et al.
Publicado: (2017)

Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation
por: Buccisano, Francesco, et al.
Publicado: (2021)

NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma
por: Coppola, Andrea, et al.
Publicado: (2015)

Can Polycythemia Vera Evolve from Acute Myeloid Leukemia? Report of a Case Showing a Simultaneous Minor JAK2 V617F Mutated Clone
por: Borsellino, Beatrice, et al.
Publicado: (2022)

Diagnostic Performance and Safety of Bronchoalveolar Lavage in Thrombocytopenic Haematological Patients for Invasive Fungal Infections Diagnosis: A Monocentric, Retrospective Experience
por: Cefalo, Mariagiovanna, et al.
Publicado: (2019)

FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance
por: Caratelli, Sara, et al.
Publicado: (2017)

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications
por: Del Principe, Maria Ilaria, et al.
Publicado: (2016)

Treatment of Acute Myeloid Leukemia with 20–30% Bone Marrow Blasts
por: Maurillo, Luca, et al.
Publicado: (2013)

The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19
por: Cristiano, Antonio, et al.
Publicado: (2022)

Coexistence of T-Large Granular Lymphocyte Leukemia and Peripheral T Cell Lymphoma-NOS with Indolent Behavior
por: Guarnera, Luca, et al.
Publicado: (2022)

Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage
por: Arriga, Roberto, et al.
Publicado: (2015)

Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy
por: Sarlo, Chiara, et al.
Publicado: (2013)

Reliability of flow-cytometry in diagnosis and prognostic stratification of myelodysplastic syndromes: correlations with morphology and mutational profile
por: Guarnera, Luca, et al.
Publicado: (2023)

Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy
por: Del Principe, Maria Ilaria, et al.
Publicado: (2014)

P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA
por: Venditti, Adriano, et al.
Publicado: (2023)

Targeted therapy in NPM1-mutated AML: Knowns and unknowns
por: Wang, Rong, et al.
Publicado: (2022)

Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia: a multicenter report from the Campus ALL Network
por: Del Principe, Maria Ilaria, et al.
Publicado: (2019)

Tissue-agnostic cancer drugs in the fight against molecular subsets of metastases of unknown origin
por: Roncati, Luca, et al.
Publicado: (2019)

P1686: LONG-TERM COMORBIDITY AND HEALTH PROBLEMS IN ACUTE MYELOID LEUKEMIA (AML) SURVIVORS: AN INTERNATIONAL AML SURVIVORSHIP STUDY
por: Efficace, Fabio, et al.
Publicado: (2023)

The effect of COVID-19 on the frequency of Pneumocystis jirovecii pneumonia: a monocentric, retrospective, and observational study
por: Del Prete, Valentina, et al.
Publicado: (2023)

P523: THE COMPARISON OF VFLAI, FLAI AND 3 + 7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD
por: Piciocchi, Alfonso, et al.
Publicado: (2023)

Characterization of FLT3-ITD(mut) acute myeloid leukemia: molecular profiling of leukemic precursor cells
por: Travaglini, Serena, et al.
Publicado: (2020)

Regulation of endogenous cardiomyocyte proliferation: The known unknowns
por: Secco, Ilaria, et al.
Publicado: (2023)

Proteomic Investigation of the Role of Nucleostemin in Nucleophosmin-Mutated OCI-AML 3 Cell Line
por: Cela, Ilaria, et al.
Publicado: (2022)

P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL
por: Tettero, Jesse, et al.
Publicado: (2023)

Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment
por: Sconocchia, Giuseppe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fc3jaj58obm36oqa9ejvhjosia